[go: up one dir, main page]

ES2099075T3 - Conjugados de antraciclina con un nuevo engarce y procedimientos para su produccion. - Google Patents

Conjugados de antraciclina con un nuevo engarce y procedimientos para su produccion.

Info

Publication number
ES2099075T3
ES2099075T3 ES90109268T ES90109268T ES2099075T3 ES 2099075 T3 ES2099075 T3 ES 2099075T3 ES 90109268 T ES90109268 T ES 90109268T ES 90109268 T ES90109268 T ES 90109268T ES 2099075 T3 ES2099075 T3 ES 2099075T3
Authority
ES
Spain
Prior art keywords
anthracicline
conjugates
production
procedures
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90109268T
Other languages
English (en)
Inventor
Robert S Greenfield
Gary R Braslawsky
Lee J Olech
Takushi Kaneko
Peter A Kiener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/353,729 external-priority patent/US5122368A/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2099075T3 publication Critical patent/ES2099075T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

EL RPESENTE INVENTO SE REFIERE A CONJUGADOS NUEVOS, METODOS PARA SU PRODUCCION, COMPOSICIONES FARMACEUTICAS Y METODOS PARA ENVIAR ANTRACICLINAS CITOTOXICAS A UNA POBLACION SELECCIONADA DE CELULAS QUE SE DESEA ELIMINAR. LOS CONJUGADOS CON=MPRENDEN AL MENOS UNA MOLECULA DE ANTRACICLINA ENLAZADA A UN LIGANDO QUE ES REACTIVO CON UNA POBLACION CELULAR A ELIMINAR, TENIENDO LA ANTRACICLINA UN GRUPO KETO EN LA POSICION C-13, Y ESTANDO UNIDA AL LIGANDO A TRAVES DE UN ENLACE Y ESTANDO LIGADA A ESTE POR UN ENLACE ADE ACILHIDRAZONA SENSIBLE AL ACIDO EN LA POSICION 13-KETO DE LA ANTRACICLINA. LOS CONJUGADOS DEL INVENTO SON UTILES PARA DROGAS DE ENVIO DE ANTICUERPOS PARA LA ELIMINACION PREFERENTE DE UNA POBLACION SELECCIONADA DE CELULAS, EN EL TRATAMIENTO DE ENFERMEDADES TALES COMO EL CANCER Y OTROS TUMORES, ETC.
ES90109268T 1989-05-17 1990-05-16 Conjugados de antraciclina con un nuevo engarce y procedimientos para su produccion. Expired - Lifetime ES2099075T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/353,729 US5122368A (en) 1988-02-11 1989-05-17 Anthracycline conjugates having a novel linker and methods for their production

Publications (1)

Publication Number Publication Date
ES2099075T3 true ES2099075T3 (es) 1997-05-16

Family

ID=23390328

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90109268T Expired - Lifetime ES2099075T3 (es) 1989-05-17 1990-05-16 Conjugados de antraciclina con un nuevo engarce y procedimientos para su produccion.

Country Status (19)

Country Link
EP (1) EP0398305B1 (es)
JP (1) JP3062696B2 (es)
KR (1) KR0136899B1 (es)
AT (1) ATE150321T1 (es)
AU (1) AU631638B2 (es)
CA (1) CA2016584C (es)
DE (1) DE69030213T2 (es)
DK (1) DK0398305T3 (es)
ES (1) ES2099075T3 (es)
FI (1) FI102356B (es)
GR (1) GR3023784T3 (es)
HK (1) HK1005018A1 (es)
IE (1) IE81109B1 (es)
IL (1) IL94379A (es)
MY (1) MY131039A (es)
NO (1) NO300691B1 (es)
NZ (1) NZ233696A (es)
PT (1) PT94064B (es)
ZA (1) ZA903757B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU638971B2 (en) * 1990-02-14 1993-07-15 Bristol-Myers Squibb Company Anthracycline immunoconjugates having a novel linker and methods for their production
CA2048089A1 (en) * 1990-09-17 1992-03-18 Wolfgang A. Wrasidlo Chemical conjugation of morpholino anthracyclines to antibodies
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
RU2119354C1 (ru) * 1996-01-05 1998-09-27 Виктор Савельевич Гуревич Способ направленного транспорта фармакологических препаратов путем их конъюгации с аргинил-глицил-аспартил (rgd) содержащими пептидами
US7033765B1 (en) 1997-02-20 2006-04-25 Toronto Research Chemicals, Inc. Site-specific drug delivery
DE69830305T2 (de) * 1997-02-20 2006-02-02 Dime, David S., Toronto Ortsspezifische arzneimittel verabreichung
GB9724838D0 (en) * 1997-11-26 1998-01-21 Franks Christopher R Compositions
IL153586A0 (en) * 2000-06-28 2003-07-06 Ward Page Faulk Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
AU2002216864A1 (en) * 2000-12-21 2002-07-01 Mcgill University Conjugates of antibodies and anticancer drugs
NZ511705A (en) * 2001-05-14 2004-03-26 Horticulture & Food Res Inst Methods and rapid immunoassay device for detecting progesterone and other steroids
KR100507968B1 (ko) 2001-08-18 2005-08-17 한국과학기술연구원 자기집합체를 형성하는 항암제-키토산 복합체 및 그의제조방법
NZ564694A (en) 2003-04-22 2009-11-27 Sod Conseils Rech Applic Peptide vectors
US9011880B2 (en) 2003-10-21 2015-04-21 Igf Oncology, Llc Compounds and methods for treating cancer
WO2005041865A2 (en) * 2003-10-21 2005-05-12 Igf Oncology, Llc Compounds and method for treating cancer
ES2533695T3 (es) * 2004-03-02 2015-04-14 Seattle Genetics, Inc. Anticuerpos cargados parcialmente y métodos para su conjugación
EP1695717A1 (en) * 2005-02-23 2006-08-30 Ludwig-Maximilians-Universität Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells
US8900589B2 (en) 2008-07-15 2014-12-02 Genetech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
US9675671B2 (en) 2014-01-12 2017-06-13 Igf Oncology, Llc Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
JP6622293B2 (ja) * 2014-09-12 2019-12-18 ジェネンテック， インコーポレイテッド アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
CN110636867B (zh) 2017-05-21 2023-09-05 Igf肿瘤公司 胰岛素样生长因子——用于治疗骨髓增生异常综合症的化学治疗缀合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957755A (en) * 1967-10-18 1976-05-18 Rhone-Poulenc S.A. Naphthacene derivatives
US4112217A (en) * 1977-09-02 1978-09-05 Sri International Bis-hydrazones of daunomycin and adriamycin
US4263428A (en) * 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4950738A (en) * 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US5162512A (en) * 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies
GB8610551D0 (en) * 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
AU638971B2 (en) * 1990-02-14 1993-07-15 Bristol-Myers Squibb Company Anthracycline immunoconjugates having a novel linker and methods for their production

Also Published As

Publication number Publication date
JP3062696B2 (ja) 2000-07-12
ZA903757B (en) 1992-01-29
EP0398305A3 (en) 1991-03-20
IL94379A (en) 1997-02-18
KR900017597A (ko) 1990-12-19
CA2016584C (en) 1999-06-29
DE69030213T2 (de) 1997-10-16
FI102356B1 (fi) 1998-11-30
EP0398305A2 (en) 1990-11-22
JPH0327321A (ja) 1991-02-05
DE69030213D1 (de) 1997-04-24
ATE150321T1 (de) 1997-04-15
FI102356B (fi) 1998-11-30
MY131039A (en) 2007-07-31
FI902387A0 (fi) 1990-05-14
PT94064A (pt) 1991-01-08
PT94064B (pt) 1997-07-31
KR0136899B1 (ko) 1998-04-25
IE81109B1 (en) 2000-03-08
DK0398305T3 (da) 1997-06-23
CA2016584A1 (en) 1990-11-17
EP0398305B1 (en) 1997-03-19
AU631638B2 (en) 1992-12-03
NO300691B1 (no) 1997-07-07
GR3023784T3 (en) 1997-09-30
HK1005018A1 (en) 1998-12-18
IE901764L (en) 1990-11-17
IL94379A0 (en) 1991-03-10
NO902197D0 (no) 1990-05-16
NO902197L (no) 1990-11-19
NZ233696A (en) 1992-04-28
AU5511790A (en) 1990-11-22

Similar Documents

Publication Publication Date Title
ES2099075T3 (es) Conjugados de antraciclina con un nuevo engarce y procedimientos para su produccion.
AR020070A1 (es) UN CONJUGADO DE POLIOL-INTERFERoN BETA, UN PROCESO PARA SU PRODUCCIoN, Y UNA COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE.
NO890593L (no) Fremgangsmaate for fremstilling av anthracyklin-immunokonjugater.
BR112022020124A2 (pt) Conjugado anticorpo-fármaco
ES2118109T3 (es) Antigenos polisacaridos de streptococcus pneumoniae.
ES2080837T5 (es) Uso de acido hialuronico en combinacion con acido ascorbico, agentes antitumorales y/o faine para el tratamiento del cancer.
AR052041A1 (es) Inmunoconjugados de anti - integrina, metodos y usos
IT1235358B (it) Derivati 17beta-oh 19-nor steroidei sostituiti in 17alfa, procedimento di preparazione, loro impiego come medicamenti e composizioni farmaceutiche che li compongono
ES2054949T3 (es) Precursores de dopamina.
ES2051738T3 (es) Derivados aminicos de compuestos analogos a acido folico.
CN110167596A (zh) 用于药物递送和稳定化的复合物及其制备方法
WO2022010797A3 (en) Maytansinoids as adc payloads and their use for the treatment of cancer
AR130757A1 (es) Conjugado de anticuerpo-fármaco y método para su preparación y uso
BR9907912A (pt) Composição, processos para tratar câncer, para eliciar linfócitos t que se infiltram em um tumor de um mamìfero, para eliciar uma resposta de hipersensibilidade do tipo retardo a um tumor de um mamìfero, e para preparar membranas de células tumorais modificadas com hapteno, e, membrana isolada de célula tumoral de mamìfero
WO2024050031A3 (en) Novel camptothecin derivatves as antibody-drug conjugates (adc) payloads
Mehra et al. The relationship between endometrial mast cell count and bleeding in women following insertion of an intrauterine device
MX2024009740A (es) Conjugado de anticuerpo-farmaco pegilado que contiene grupos hidroxilo.
ES436179A1 (es) Procedimiento para intensificar la eficacia de medicamentos que in vivo o in vitro demuestren una afinidad de enlace a proteinas de la sangre.
CO5300468A1 (es) Antigeno asociado con tumores
ATE82128T1 (de) Pharmazeutische zusammensetzungen zur behandlung von krebs.
TW202545955A (zh) 亞胺基-蒽環衍生物及方法
IT7849218A0 (it) Derivati del pregn 4-ene procedimento per la loro produzione e composizioni farmaceutiche che licontengono come ingredienti attivi
ES2086413T3 (es) Utilizacion de agentes antigestagenos para la preparacion de medicamentos.
IT7921321A0 (it) Derivati del paracetamolo ad azione terapeutica, procedimento per laloro preparazione e composizioni farmaceutiche relative.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 398305

Country of ref document: ES